Extended Data Fig. 8: Peripheral drug effects.
From: GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice
a–p, DIO mice were treated with a singly s.c. injection of GLP-1:GIP, GLP-1:GIP:Lani or vehicle, followed by tissue harvesting 7 h post treatment. 100 nmol kg−1. a,h,k,n, Principal component analysis (PCA) in pancreas (a), eWAT (h), liver (k) and skeletal muscle (n). b,i,l,o, Venn-diagram with differentially regulated proteins (DRPs) over vehicle in pancreas (b), eWAT (i), liver (l) and skeletal muscle (o). c,j,m,p, Heatmaps with supervised hierarchical clustering of z-scored intensities for DRPs in pancreas (c), eWAT (j), liver (m) and skeletal muscle (p). d–g, Selected enriched annotations. d, Cluster 1. e, Cluster 2. f, Cluster 3. g, Cluster 4. Data were analysed using one-way ANOVA, FDR < 0.05 with Tukey’s HSD post hoc test (b,i,l,o), Fisher’s exact test with Benjamini–Hochberg FDR adjustment (d–g), or one-way ANOVA, FDR < 0.05 (c,j,m,p). Data are mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001. Data in panel a–g comprise n = 10 per group. Data in panel h–j,k–m comprise n = 10 Vhcl, n = 9 GLP-1:GIP and n = 10 GLP-1:GIP:Lani. Data in panel n–p comprise n = 9 Vhcl, n = 10 GLP-1:GIP and n = 10 GLP-1:GIP:Lani. Exact P-values, n-values and detailed statistics are provided in Supplementary Tables 1 and 3 and the Data Source File.
